Show simple item record

dc.contributor.authorHawnaur, J M
dc.contributor.authorJohnson, Richard J
dc.contributor.authorRead, G
dc.contributor.authorIsherwood, I
dc.date.accessioned2010-05-21T14:13:13Z
dc.date.available2010-05-21T14:13:13Z
dc.date.issued1993-05
dc.identifier.citationMagnetic resonance imaging with Gadolinium-DTPA for assessment of bladder carcinoma and its response to treatment. 1993, 47 (5):302-10 Clin Radiolen
dc.identifier.issn0009-9260
dc.identifier.pmid8508591
dc.identifier.doi10.1016/S0009-9260(05)81444-8
dc.identifier.urihttp://hdl.handle.net/10541/99596
dc.description.abstractMagnetic Resonance Imaging (MRI) with intravenous Gadolinium-DTPA (Gd-DTPA, Magnevist, Schering-AG) was performed in 44 patients, 32 with primary bladder carcinoma and 12 with suspected recurrence after treatment. Gd-DTPA often increased diagnostic confidence in the identification and staging of tumours confined to the bladder wall and was necessary to assess depth of bladder wall invasion when T2-weighted images were suboptimal. Enhancement after Gd-DTPA enabled distinction between necrotic and viable tumour and blood clot. There was little advantage in its use for tumours infiltrating perivesical fat or with metastases to lymph nodes or bone, in the absence of a fat suppression sequence. Gd-DTPA may therefore be useful in selected patients with tumours of Stage T3a or less in whom information about depth of bladder wall invasion is inadequately shown on pre-contrast sequences. Artefacts due to variable and inhomogeneous urine signal intensity, however, often degraded post-Gd-DTPA images of the bladder. Changes in the bladder due to radiotherapy were observed on MRI 3-4 months after treatment in patients referred for routine follow-up and in some patients with suspected recurrence. Mucosal hyperintensity, thickening and abnormal signal intensity of the muscular layers of the bladder wall, with enhancement after Gd-DTPA were demonstrated. Such changes obscured small volume or superficial recurrence of tumour after radiotherapy. Abnormal enhancement was also observed in pelvic organs and soft tissues irradiated several years earlier. Enhancement after Gd-DTPA does not therefore reliably distinguish between recurrent tumour and radiotherapy change.
dc.language.isoenen
dc.subjectCancer Recurrenceen
dc.subjectCancer Stagingen
dc.subjectUrinary Bladder Canceren
dc.subject.meshAged
dc.subject.meshFemale
dc.subject.meshGadolinium DTPA
dc.subject.meshHumans
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshNeoplasm Staging
dc.subject.meshOrganometallic Compounds
dc.subject.meshPentetic Acid
dc.subject.meshTreatment Outcome
dc.subject.meshUrinary Bladder Neoplasms
dc.titleMagnetic resonance imaging with Gadolinium-DTPA for assessment of bladder carcinoma and its response to treatment.en
dc.typeArticleen
dc.contributor.departmentDepartment of Diagnostic Radiology, University of Manchester.en
dc.identifier.journalClinical Radiologyen
html.description.abstractMagnetic Resonance Imaging (MRI) with intravenous Gadolinium-DTPA (Gd-DTPA, Magnevist, Schering-AG) was performed in 44 patients, 32 with primary bladder carcinoma and 12 with suspected recurrence after treatment. Gd-DTPA often increased diagnostic confidence in the identification and staging of tumours confined to the bladder wall and was necessary to assess depth of bladder wall invasion when T2-weighted images were suboptimal. Enhancement after Gd-DTPA enabled distinction between necrotic and viable tumour and blood clot. There was little advantage in its use for tumours infiltrating perivesical fat or with metastases to lymph nodes or bone, in the absence of a fat suppression sequence. Gd-DTPA may therefore be useful in selected patients with tumours of Stage T3a or less in whom information about depth of bladder wall invasion is inadequately shown on pre-contrast sequences. Artefacts due to variable and inhomogeneous urine signal intensity, however, often degraded post-Gd-DTPA images of the bladder. Changes in the bladder due to radiotherapy were observed on MRI 3-4 months after treatment in patients referred for routine follow-up and in some patients with suspected recurrence. Mucosal hyperintensity, thickening and abnormal signal intensity of the muscular layers of the bladder wall, with enhancement after Gd-DTPA were demonstrated. Such changes obscured small volume or superficial recurrence of tumour after radiotherapy. Abnormal enhancement was also observed in pelvic organs and soft tissues irradiated several years earlier. Enhancement after Gd-DTPA does not therefore reliably distinguish between recurrent tumour and radiotherapy change.


Files in this item

This item appears in the following Collection(s)

Show simple item record